|Articles|March 1, 2016
- Pharmaceutical Executive-03-01-2016
- Volume 36
- Issue 3
Pharmaceutical Executive, March 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 9 years ago
What Errors Do We Miss in Clinical Trials?over 9 years ago
Data Disclosure: Sealing the Error Envelopeover 9 years ago
Vaccines 2016: Big Bets for Global Threatsover 9 years ago
Drug Delivery Roundtable: More than the Pillover 9 years ago
Orphans of the Stormover 9 years ago
Country Report: The NetherlandsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Merck to Acquire Cidara for $9.2 Billion
3
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
4
DEI Changes in Pharma: A Look Back at 2025 & Predictions for 2026
5
